

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

CIPLA LTD.,  
Petitioner

v.

ABRAXIS BIOSCIENCE, LLC,  
Patent Owner

---

Case IPR2018-00162  
Patent 7,820,788 B2  
Issued: October 26, 2010

Title: COMPOSITIONS AND METHODS OF  
DELIVERY OF PHARMACOLOGICAL AGENTS

---

**PETITION FOR *INTER PARTES* REVIEW**

## TABLE OF CONTENTS

	<b>Page</b>
I. INTRODUCTION .....	1
II. OVERVIEW .....	4
III. MANDATORY NOTICES .....	5
IV. REQUIREMENTS FOR REVIEW .....	7
V. LEVEL OF ORDINARY SKILL IN THE ART .....	8
VI. THE PRIOR ART AND THE '788 PATENT .....	8
A. Taxol <sup>®</sup> (paclitaxel) was an FDA-approved “wonder drug,” but initially could only be administered with a toxic solvent. ....	9
B. The inventors repeatedly patented albumin-paclitaxel nanoparticles as a solution to the known problems of Taxol <sup>®</sup> .....	10
C. Desai (EX1006) specifically discloses a nanoparticle formulation with an albumin-paclitaxel ratio of 9:1. ....	12
D. Desai, Kadima (EX1004), and Liversidge (EX1005) taught varying ranges of albumin-paclitaxel ratios, and taught lowering the ratio to increase drug concentration and reduce cost.....	12
E. The inventors obtained their <i>third</i> round of patents on albumin-paclitaxel by arguing that a 9:1 ratio has “unexpected” benefits. ....	15
VII. PLAIN AND ORDINARY MEANINGS .....	19
A. “the weight ratio of albumin to paclitaxel in the composition” and “the ratio (w/w) of albumin to the paclitaxel in the pharmaceutical composition” .....	19
B. “a particle size of less than about 200 nm” .....	22
VIII. ANALYSIS OF GROUNDS FOR TRIAL .....	23

A.	GROUND I: ANTICIPATION UNDER 35 U.S.C. §102(b).....	23
1.	Claim 1 is anticipated.....	23
a.	Albumin-paclitaxel combination .....	24
b.	Particle size of less than about 200 nm .....	24
c.	Albumin-paclitaxel ratio of about 1:1 to 9:1 .....	26
2.	Claims 2–9 and 11–12 are anticipated.....	27
3.	The “starting” albumin-paclitaxel ratio does not change. ....	30
B.	GROUND II: OBVIOUSNESS UNDER 35 U.S.C. §103(a).....	34
1.	Claim 1 would have been obvious.....	34
a.	GROUND II.A: Desai alone.....	34
i.	The albumin-paclitaxel ratio of about 9:1 falls within a range disclosed by Desai. ....	37
ii.	Desai would have motivated a skilled artisan to lower Capxol <sup>TM</sup> 's albumin- paclitaxel ratio. ....	39
iii.	A skilled artisan would have reasonably expected the claimed albumin-paclitaxel ratio of 9:1 to retain stability.....	41
b.	GROUND II.B: Desai, Kadima, and Liversidge.....	44
i.	Kadima and Liversidge also disclose ranges of albumin-paclitaxel ratios including 9:1.....	45
ii.	Kadima teaches additional reasons to lower Capxol <sup>TM</sup> 's 13.3:1 ratio to about 9:1.....	47
2.	Claims 2–12 would have been obvious. ....	51
3.	There is no probative evidence of secondary considerations.....	54

a.	The allegedly “unexpected” cell-binding results lack a nexus to the ’788 patent and were expected. ....	55
b.	The allegedly “unexpected” clinical data did not compare the closest prior art and were expected.....	58
c.	Blocking patents prevented others from developing the claimed invention.....	61
IX.	CONCLUSION.....	62

**TABLE OF AUTHORITIES**

	<b>Page(s)</b>
<b>Cases</b>	
<i>Abraxis BioScience, LLC v. Actavis LLC</i> , C.A. No. 16-1925-JMV-MF .....	5
<i>Abraxis BioScience, LLC v. Cipla Ltd.</i> , C.A. No. 16-9074-JMV-MF .....	5
<i>Agrizap, Inc. v. Woodstream Corp.</i> , 520 F.3d 1337 (Fed. Cir. 2008) .....	54
<i>Amneal Pharms., LLC v. Supernus Pharms., Inc.</i> , IPR2013-00368, Paper 8 (PTAB Dec. 17, 2013) .....	54
<i>Apotex, Inc. v. Cephalon, Inc.</i> , 2012 WL 1080148 (E.D. Pa. Mar. 28, 2012) .....	22
<i>Arthrocare Care Corp. v. Smith &amp; Nephew, Inc.</i> , 406 F.3d 1365 (Fed. Cir. 2005) .....	26
<i>Brown &amp; Williamson Tobacco Corp. v. Philip Morris Inc.</i> , 229 F.3d 1120 (Fed. Cir. 2000) .....	49
<i>Exxon Chem. Patents, Inc. v. Lubrizol Corp.</i> , 64 F.3d 1553 (Fed. Cir. 1995) .....	21
<i>Galderma Labs., L.P. v. Tolmar, Inc.</i> , 737 F.3d 731 (Fed. Cir. 2013) .....	4, 38, 61
<i>In re Ethicon, Inc.</i> , 844 F.3d 1344 (Fed. Cir. 2017) .....	39
<i>In re Geisler</i> , 116 F.3d 1465 (Fed. Cir. 1997) .....	38
<i>In re GPAC Inc.</i> , 57 F.3d 1573 (Fed. Cir. 1995) .....	55
<i>In re Harris</i> , 409 F.3d 1339 (Fed. Cir. 2005) .....	46, 53

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.